{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:47:26Z","timestamp":1791388046924,"version":"4.3.3"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.coi.2017.07.016","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T03:32:59Z","timestamp":1504236779000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Check point inhibitors as therapies for infectious diseases"],"prefix":"10.1016","volume":"48","author":[{"given":"Maureen A","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nechanitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak W","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2017.07.016_bib0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2009.06.036","article-title":"Redefining chronic viral infection","volume":"138","author":"Virgin","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.coi.2017.07.016_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","author":"Li","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coi.2017.07.016_bib0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.coi.2010.02.005","article-title":"Features of responding T cells in cancer and chronic infection","volume":"22","author":"Kim","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.coi.2017.07.016_bib0290","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.coi.2017.07.016_bib0295","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.coi.2017.07.016_bib0300","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2006-07-034066","article-title":"CTLA-4 dysregulation of self\/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent","volume":"108","author":"Gattinoni","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.coi.2017.07.016_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-002-0429-9","article-title":"A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation","volume":"54","author":"Maurer","year":"2002","journal-title":"Immunogenetics"},{"key":"10.1016\/j.coi.2017.07.016_bib0310","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.coi.2017.07.016_bib0315","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.2337\/db11-0130","article-title":"The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function","volume":"60","author":"Gerold","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.coi.2017.07.016_bib0320","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1478-3231.2011.02694.x","article-title":"Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection","volume":"32","author":"Danilovic","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.coi.2017.07.016_bib0325","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/0300060513483387","article-title":"Association between cytotoxic T-lymphocyte associated protein 4 gene +49 A\/G polymorphism and chronic infection with hepatitis B virus: a meta-analysis","volume":"41","author":"Xu","year":"2013","journal-title":"J Int Med Res"},{"key":"10.1016\/j.coi.2017.07.016_bib0330","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.humimm.2010.05.023","article-title":"CTLA-4 gene polymorphism +49 A\/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer","volume":"71","author":"Hu","year":"2010","journal-title":"Hum Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-014-0033-1","article-title":"Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series","volume":"2","author":"Ravi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coi.2017.07.016_bib0340","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2017.07.016_bib0345","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0350","doi-asserted-by":"crossref","first-page":"e1005761","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2017.07.016_bib0355","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.4049\/jimmunol.180.8.5439","article-title":"Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection","volume":"180","author":"Cecchinato","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0360","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coi.2017.07.016_sbref0365","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.coi.2017.07.016_bib0370","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coi.2017.07.016_bib0375","doi-asserted-by":"crossref","first-page":"e1000313","DOI":"10.1371\/journal.ppat.1000313","article-title":"Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1\/CTLA-4 blockade","volume":"5","author":"Nakamoto","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2017.07.016_bib0380","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2017.07.016_bib0385","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2017.07.016_bib0390","doi-asserted-by":"crossref","first-page":"e77780","DOI":"10.1371\/journal.pone.0077780","article-title":"PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads","volume":"8","author":"Seung","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2017.07.016_bib0395","doi-asserted-by":"crossref","first-page":"980","DOI":"10.4049\/jimmunol.182.2.980","article-title":"PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination","volume":"182","author":"Finnefrock","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2017.07.016_sbref0400","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2017.07.016_bib0405","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0410","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1172\/JCI43127","article-title":"Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity","volume":"120","author":"McMahan","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2017.07.016_bib0415","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/eji.201040340","article-title":"HCV-specific T cells in HCV\/HIV co-infection show elevated frequencies of dual Tim-3\/PD-1 expression that correlate with liver disease progression","volume":"40","author":"Vali","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0420","doi-asserted-by":"crossref","first-page":"e40146","DOI":"10.1371\/journal.pone.0040146","article-title":"Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection","volume":"7","author":"Sakhdari","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2017.07.016_bib0425","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s10495-014-1084-y","article-title":"Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes","volume":"20","author":"Barathan","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.coi.2017.07.016_bib0430","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2017.07.016_sbref0435","doi-asserted-by":"crossref","first-page":"20078","DOI":"10.7448\/IAS.18.1.20078","article-title":"Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients","volume":"18","author":"Sada-Ovalle","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.coi.2017.07.016_sbref0440","doi-asserted-by":"crossref","first-page":"e1005349","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2017.07.016_bib0445","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coi.2017.07.016_bib0450","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2017.07.016_bib0455","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/jgh.13017","article-title":"Lymphocyte activation gene 3 negatively regulates the function of intrahepatic hepatitis C virus-specific CD8+ T cells","volume":"30","author":"Chen","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2017.07.016_bib0460","doi-asserted-by":"crossref","first-page":"e5275","DOI":"10.1097\/MD.0000000000005275","article-title":"Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent","volume":"96","author":"Ye","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.coi.2017.07.016_sbref0465","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12977-015-0142-z","article-title":"Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment","volume":"12","author":"Juno","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.coi.2017.07.016_bib0470","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncomms1100","article-title":"B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection","volume":"1","author":"Huang","year":"2010","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2017.07.016_bib0475","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/infdis\/jiw163","article-title":"Maintenance of HIV-specific memory B-cell responses in elite controllers despite low viral burdens","volume":"214","author":"Buckner","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2017.07.016_bib0480","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1172\/JCI43271","article-title":"Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques","volume":"120","author":"Titanji","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2017.07.016_bib0485","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fimmu.2017.00046","article-title":"The role of CD4+ T follicular helper cells in HIV infection: from the germinal center to the periphery","volume":"8","author":"Thornhill","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0490","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1084\/jem.20101773","article-title":"Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells","volume":"208","author":"Fahey","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2017.07.016_bib0495","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nm.3109","article-title":"Inadequate T follicular cell help impairs B cell immunity during HIV infection","volume":"19","author":"Cubas","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2017.07.016_bib0500","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2010-12-328070","article-title":"Responsiveness of HIV-specific CD4 T cells to PD-1 blockade","volume":"118","author":"Porichis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2017.07.016_bib0505","doi-asserted-by":"crossref","first-page":"e84185","DOI":"10.1371\/journal.pone.0084185","article-title":"B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade","volume":"8","author":"Nicholas","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2017.07.016_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2017.07.016_bib0515","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coi.2017.07.016_bib0520","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1742-4690-10-74","article-title":"Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection","volume":"10","author":"Jost","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.coi.2017.07.016_bib0525","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2009.12.005","article-title":"T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B","volume":"52","author":"Ju","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2017.07.016_bib0530","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nri3799","article-title":"Balancing natural killer cell activation through paired receptors","volume":"15","author":"Martinet","year":"2015","journal-title":"Nat Rev Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279151730016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279151730016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:42:48Z","timestamp":1760604168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279151730016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":53,"alternative-id":["S095279151730016X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2017.07.016","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Check point inhibitors as therapies for infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2017.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}